Abstract
Computational methods for drug design and its application for structure-based drug design using crystallographic data and NMR solution structural data were briefly described in view of interaction of ligands with or without structures of the target receptors. Analysis of the hydrolytic mechanism of β-lactamases whose 3D stuctures has been known led to understanding a specific recognition of β-lactam antibiotics and to design of a new candidate for anti-MRSA antibiotics. Conformational analysis of peptide derivatives whose receptor structures have not known is the other example for design of new skeletons of nonpeptide compounds. Receptor-bound structure analysis of antagonist or agonist peptides suggested different conformations of the peptides. This may be due to a different receptor structure as a consequence of a large structural change of receptors upon binding of agonists.
